Skip to main content

Advertisement

SpringerLink
Log in

Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone

  • Fertility Preservation
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC).

Methods

The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment.

Results

AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p = 0.001).

Conclusions

AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276–99.

    PubMed  Google Scholar 

  2. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56:168–83.

    Article  PubMed  Google Scholar 

  3. Oktay KH, Yih M. Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips. Semin Reprod Med. 2002;20:63–74.

    Article  PubMed  Google Scholar 

  4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.

    Article  PubMed  Google Scholar 

  5. Ganz P, Hahn E. Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol. 2008;26:759–67.

    Article  PubMed  Google Scholar 

  6. American Cancer Society: Breast Cancer Facts & Figures 2005–2006. http://www.cancer.org/downloads/STT/CAFF2005BrFacspdf2005.pdf

  7. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11(5):422–34.

    Article  PubMed  CAS  Google Scholar 

  8. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.

    Article  PubMed  CAS  Google Scholar 

  9. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.

    Article  PubMed  CAS  Google Scholar 

  10. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, et al. Impact on survival time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94.

    Article  PubMed  Google Scholar 

  11. Cold S, During M, Ewertz M, Knoop A, Moller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93:627–32.

    Article  PubMed  CAS  Google Scholar 

  12. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996;81:571–6.

    Article  PubMed  CAS  Google Scholar 

  13. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77:468–71.

    Article  PubMed  Google Scholar 

  14. van Rooij IA, de Jong E, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. Fertil Steril. 2004;81:1478–85.

    Article  PubMed  Google Scholar 

  15. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod. 2001;16(5):868–70.

    Article  PubMed  CAS  Google Scholar 

  16. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. ESHRE Special Interest Group for Reproductive Endocrinology—AMH Round Table: Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod. 2009;24(9):2264–75.

    Article  PubMed  Google Scholar 

  17. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83(4):979–87.

    Article  PubMed  Google Scholar 

  18. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30.

    Article  PubMed  Google Scholar 

  19. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. Prospective, comparative analysis of anti-mullerian hormone, inhibin B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010;93(3):855–64.

    Article  PubMed  CAS  Google Scholar 

  20. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007;14(5):602–10.

    Article  PubMed  CAS  Google Scholar 

  21. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril. 2008;90:737–43.

    Article  PubMed  CAS  Google Scholar 

  22. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocytes quality in stimulated cycles. Hum Reprod. 2006;21:2022–6.

    Article  PubMed  CAS  Google Scholar 

  23. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–9.

    Article  PubMed  CAS  Google Scholar 

  24. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod. 2006;21:159–63.

    Article  PubMed  CAS  Google Scholar 

  25. Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, et al. Correlations between anti-Mullerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res. 2007;12:604–8.

    PubMed  CAS  Google Scholar 

  26. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009;24:867–75.

    Article  PubMed  CAS  Google Scholar 

  27. Guerif F, Lemseffer M, Couet ML, Gervereau O, Ract V, Royere D. Serum antimullerian hormone is not predictive of oocytes quality in vitro fertilization. Ann Endocrinol (Paris). 2009;70(4):230–4.

    CAS  Google Scholar 

  28. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss 3rd JF. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007;87(1):101–6.

    Article  PubMed  CAS  Google Scholar 

  29. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91:705–14.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study is partially supported by NIH HD 053112.

Author information

Authors and Affiliations

  1. Institute for Fertility Preservation and Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, Valhalla, NY, 10595, USA

    Sanghoon Lee, Sinan Ozkavukcu, Elke Heytens, Rose M. Alappat & Kutluk Oktay

  2. Biometrics, Data Management and PK/PD Unit, Graduate School of Basic Medical Sciences, Department of Pathology, New York Medical College, Valhalla, NY, 10595, USA

    Fred Moy

Authors
  1. Sanghoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sinan Ozkavukcu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elke Heytens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fred Moy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rose M. Alappat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kutluk Oktay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kutluk Oktay.

Additional information

Capsule

AMH and AFC are the most reliable serum and biophysical markers of embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, S., Ozkavukcu, S., Heytens, E. et al. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet 28, 651–656 (2011). https://doi.org/10.1007/s10815-011-9567-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-011-9567-z

Keywords

Search

Navigation